THYROCARE · NSE
Thyrocare Technologies Limited
₹555.8
-0.62% (-₹3.45)
Prev. close
₹559.25
Volume
2,44,576
Delivery %
63.5%
As of
18 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Thyrocare Technologies Limited
Thyrocare Technologies Limited provides diagnostic testing services to patients, laboratories, and hospitals in India. It operates through three segments: Diagnostic Testing Services, Imaging Services, and Others. The Diagnostic Testing Services segment engages in the selling of consumables used for collection, and promotion of pathology. The Imaging Services segment sells radio-pharmaceutical and consumables for reporting. The Others segment engages in the sale of glucometer and glucostrips under the brand name sugarscan. The company offers diagnostic and pathological services. The company was founded in 1996 and is based in Navi Mumbai, India. Thyrocare Technologies Limited is a subsidiary of Docon Technologies Private Limited.
Details
Sector
Healthcare
Industry
Diagnostics & Research
CEO
Mr. Rahul Franklin Guha
Headquarters
Navi Mumbai
Employees
1,906
Website
thyrocare.comExchange
View on NSE ↗Key stats
Market cap
₹8,889.18 Cr
P/E ratio (TTM)
48.9
Dividend yield
3.02%
EPS (TTM)
₹11.41
Beta (1Y · daily vs NIFTY 50)
0.53
Beta (5Y · monthly vs NIFTY 50)
0.94
Shares float
7.80 Cr
EPS · quarter ended Jun 2026
₹3.22
Financial Performance
01 · Financials
Revenue for Mar 2021–Mar 2022 is as filed with BSE (consolidated), and the first plotted growth figure is computed against Mar 2020 revenue as filed with BSE; the two sources' revenue definitions differ by 1.8% on Mar 2023. FY22 growth needs FY21 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹494.62 Cr | ₹588.86 Cr | ₹526.67 Cr | ₹571.88 Cr | ₹687.35 Cr | ₹829.04 Cr | |
| EBITDA | ₹183.68 Cr | ₹264.14 Cr | ₹129.65 Cr | ₹146.80 Cr | ₹205.19 Cr | ₹272.87 Cr |
| ₹113.14 Cr | ₹176.14 Cr | ₹64.49 Cr | ₹70.76 Cr | ₹91.51 Cr | ₹163.04 Cr | |
| Diluted EPS | ₹7.12 | ₹11.08 | ₹4.05 | ₹4.47 | ₹5.69 | ₹10.24 |
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹545.80 Cr | ₹607.66 Cr | ₹632.72 Cr | ₹643.88 Cr | ₹692.75 Cr | ₹747.22 Cr | |
| ₹8.49 Cr | ₹20.70 Cr | ₹23.31 Cr | ₹42.34 Cr | ₹24.68 Cr | ₹50.69 Cr | |
| Stockholders' equity | ₹427.28 Cr | ₹526.57 Cr | ₹534.30 Cr | ₹526.77 Cr | ₹546.75 Cr | ₹585.50 Cr |
Long-term debt, Current (short-term) debt, Others have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹116.30 Cr | ₹266.99 Cr | ₹129.31 Cr | ₹167.64 Cr | ₹179.91 Cr | ₹213.24 Cr | |
| Investing cash flow | ₹-50.23 Cr | ₹-119.71 Cr | ₹-38.99 Cr | ₹-91.29 Cr | ₹-41.11 Cr | ₹-23.01 Cr |
| ₹-61.57 Cr | ₹-146.85 Cr | ₹-86.18 Cr | ₹-84.80 Cr | ₹-130.42 Cr | ₹-169.59 Cr | |
| Capital expenditure | ₹-164.37 Cr | ₹-212.70 Cr | ₹-43.65 Cr | ₹-61.58 Cr | ₹-33.48 Cr | ₹-20.88 Cr |
| End cash position | ₹13.20 Cr | ₹13.63 Cr | ₹17.77 Cr | ₹9.32 Cr | ₹17.68 Cr | ₹38.32 Cr |
Debt issued, Debt repaid have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21 | Dec 21–Jun 22(3Q) | Sep 22–Sep 23(5Q) | Dec 23–Sep 24(4Q) | Dec 24–Sep 25(4Q) | Dec 25–Dec 25(2Q) | Mar 26–Jun 26(2Q) |
|---|---|---|---|---|---|---|---|
| Promoter | 71.22% | 71.18% | 71.14% | 71.11% | 71.06% | 60.93% | 60.92% |
| Public | 28.78% | 28.82% | 28.86% | 28.89% | 28.94% | 39.07% | 39.08% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Thyrocare Technologies Limited | ₹8,874.86 Cr | ₹559.25 | 50.5 | 15.16 | 27.8% | 0.09 | +20.7% | -53.7% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 11
Concall transcripts
Show all 12
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
10 indices
NSE weights are a free-float market-cap-share estimate, not NSE’s own published (and sometimes capped) index weight. BSE weights are BSE’s own published index weight, not an estimate. Indices without weight data are listed without one, in alphabetical order after the weighted ones.
API Holdings: Acquires 51.02% Stake in Thyrocare Technologies
API Holdings Limited has acquired 51.02% of Thyrocare Technologies Limited's paid-up share capital, totaling 8,12,00,000 equity shares. This follows the amalgamation of Docon Technologies Private Limited with API Holdings, effective September 3, 2026, after NCLT sanction. The transaction significantly alters Thyrocare's ownership.